These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16255666)

  • 1. Safety of obesity drugs.
    Greenway FL; Caruso MK
    Expert Opin Drug Saf; 2005 Nov; 4(6):1083-95. PubMed ID: 16255666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug treatment of obesity].
    Svendsen OL; Toubro S; Breum L; Bruun JM; Astrup AV
    Ugeskr Laeger; 2006 Jan; 168(2):163-7. PubMed ID: 16403342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological concepts for the treatment of obesity - a therapeutic meander?].
    Schindler C; Chavakis T; Lamounier-Zepter V; Bornstein SR
    Dtsch Med Wochenschr; 2011 Aug; 136(31-32):1570-3. PubMed ID: 21809243
    [No Abstract]   [Full Text] [Related]  

  • 4. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
    Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
    Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?
    Maccarrone M; Wang H; Dey SK
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):456-7. PubMed ID: 17302885
    [No Abstract]   [Full Text] [Related]  

  • 6. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
    Ward SJ; Raffa RB
    Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolic syndrome treatment strategies.
    Fujioka K
    Pharmacotherapy; 2006 Dec; 26(12 Pt 2):222S-226S. PubMed ID: 17125449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A drug for therapy of obesity: really only life style? (interview by Dirk Einecke)].
    Wirth A
    MMW Fortschr Med; 2006 Nov; 148(46):17. PubMed ID: 17615781
    [No Abstract]   [Full Text] [Related]  

  • 9. The safety of obesity drugs.
    Van Gaal LF; Scheen AJ; Formiguera X
    Expert Opin Drug Saf; 2007 Sep; 6(5):475-6; author reply 477-8. PubMed ID: 17877434
    [No Abstract]   [Full Text] [Related]  

  • 10. Appetite downer awaits approval.
    Wadman M
    Nature; 2005 Sep; 437(7059):618-9. PubMed ID: 16193017
    [No Abstract]   [Full Text] [Related]  

  • 11. Melancholic features related to rimonabant.
    de Mattos Viana B; Prais HA; Daker MV
    Gen Hosp Psychiatry; 2009; 31(6):583-5. PubMed ID: 19892218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The endocannabinoid system and treatment of obesity].
    Aronsen L
    Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy for obesity.
    Li M; Cheung BM
    Br J Clin Pharmacol; 2009 Dec; 68(6):804-10. PubMed ID: 20002075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy for obese adolescents.
    Greydanus DE; Bricker LA; Feucht C
    Pediatr Clin North Am; 2011 Feb; 58(1):139-53, xi. PubMed ID: 21281853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical aspects of the treatment of obesity by drugs: a review.
    Munro JF
    Int J Obes; 1979; 3(2):171-80. PubMed ID: 393645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
    Padwal RS; Majumdar SR
    Lancet; 2007 Jan; 369(9555):71-7. PubMed ID: 17208644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New drugs; rimonabant].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panel advises against rimonabant approval.
    Traynor K
    Am J Health Syst Pharm; 2007 Jul; 64(14):1460-1. PubMed ID: 17617490
    [No Abstract]   [Full Text] [Related]  

  • 19. The challenge of treating obesity: the endocannabinoid system as a potential target.
    Isoldi KK; Aronne LJ
    J Am Diet Assoc; 2008 May; 108(5):823-31. PubMed ID: 18442506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
    Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.